FEATURED EVENT
This conference will establish dialogue and discussion among Industry and Health Authorities to inform, teach, and share product development and regulatory information in the areas of nonclinical, chemistry, manufacturing and control (CMC) and clinical development of oligonucleotide-based therapeutic drugs, including antisense, RNAi, immunostimulatory and aptamer applications.

ABOUT THE KEYNOTE SPEAKER
John J. Rossi, PhD
Beckman Research Institute of the City of Hope, Duarte, CA.
Dr. Rossi is Professor and Chair of the Division of Molecular Biology, Beckman Research Institute of the City of Hope, and Dean, Graduate School of Biological Sciences, Beckman Research Institute of the City of Hope. Dr. Rossi received his doctoral training in genetics under Dr. Claire Berg at the University of Connecticut in Storrs and postdoctoral training in molecular genetics under Dr. Arthur Landy at Brown University. In the 1980s and 1990s his research focused on the mechanism of action and clinical applications of catalytic RNAs, or ribozymes. His group was the first to demonstrate that hammerhead ribozymes could be used for inhibition of HIV replication. This research program led to two clinical trials in which ribozyme genes have been transduced into hematopoietic stem cells for autologous transplant in HIV infected individuals. He is the recipient of an NIH Merit award for his work on ribozymes and HIV. Work in the laboratory continues to focus upon RNA based therapies, with recent emphasis on function and applications of expressed short hairpin RNAs for therapeutic treatment of HIV and cancers. This research has led to a planned clinical trial for RNAi based therapy of HIV infection in a gene therapy setting. He has published over 200 peer reviewed articles and numerous reviews and commentaries on RNAi based therapeutics.

FEATURED SESSIONS
- Mechanisms of Action and Therapeutic Potential
- General Issues in Safety Assessment
- Analytical Characterization for ODN Therapeutics
- Clinical and Regulatory Challenges of Antisense and Antisense-like Technologies in Clinical Oncology
- Specific Issues in the Safety Assessment of Oligonucleotide-based Therapeutics
- Oligonucleotides for Infectious Diseases: Issues and Opportunities
- Challenges in Process Development for Oligonucleotide Synthesis
- General Issues In the ADME Properties of Oligonucleotide Drugs
- Novel Delivery Systems
- Advances and Issues in the Development of Oligonucleotides for The Therapy of Lung Diseases
- CMC Regulatory Considerations
- Oligonucleotides – Emerging Therapies in Treatment of Retinal Diseases
- Specific Issues in ADME
- Use of ODN TLR9 Agonists as Vaccine Adjuvants: Clinical Experience
- Non Clinical and Clinical Summary and Next Steps

TARGET AUDIENCE
This program will benefit professionals involved in

- Biotechnology
- Drug discovery
- Biologics
- Chemistry, manufacturing, and quality assurance
- Vaccines
- Clinical, regulatory, and business development

CONTACT INFORMATION
Conference: Joanne Wallace Phone +1-215-442-6180 email Joanne.Wallace@diahome.org

VISIT WWW.DIAHOME.ORG FOR A COMPLETE SCHEDULE OF EVENTS!
DIA, 800 Enterprise Road, Suite 200, Horsham, PA 19044, USA tel: +1-215-442-6100 fax: +1-215-442-6199 email: dia@diahome.org
Oligonucleotide-based therapeutics encompass a wide range of properties, in terms of their mechanism of action and their medical applications. This field has evolved from the traditional strategies of targeting specific mRNA destruction by way of antisense technology to include more recent approaches such as siRNA, oligonucleotide-protein interactions in the form of “aptamers” and immunostimulation through binding to Toll-like receptors (TLR). In this session, leading experts in the field of antisense, immunostimulatory ODNs, siRNA and aptamers will describe the mechanisms of action behind these therapeutic approaches and their potential to treat patients.

**Antisense Mechanisms**
C. Frank Bennett, PhD
Senior Vice President, Research, Isis Pharmaceuticals, Inc.

**Mechanisms and Therapeutic Applications of Oligodeoxynucleotide Toll-like Receptor 9 Agonists**
Arthur M. Krieg, MD
Senior Vice President, Research and Development
Chief Scientific Officer, Coley Pharmaceutical Group, Inc.

**Progress, Opportunities and Challenges in the Development of Therapeutic siRNAs**
Akshay Vaishnaw, MD, PhD
Vice President, Clinical Research, Alnylam Pharmaceuticals, Inc.

**Aptamers, A Whole Different Kind of Oligonucleotide Therapeutic**
Page Bouchard, DVM
Senior Vice President, Nonclinical Research & Development
Archemix Corporation
SESSION 2

GENERAL ISSUES IN SAFETY ASSESSMENT, PART 1

SESSION CHAIRPERSON

Arthur A. Levin, PhD
Senior Vice President of Development, Isis Pharmaceuticals, Inc.

This session will provide background information on the safety assessment of oligonucleotide-based therapeutics. Each speaker will address briefly what the issues are with the oligonucleotide class that they are working on and they will point out similarities and differences between the classes. The speakers will discuss briefly both how compounds are being tested as well as the results. The goal of this session is to provide the background understanding needed in order to address specific issues in the following sessions. The talks will be designed to provide all participants at the conference (clinical and manufacturing) an overview of the issues surrounding the assessment of safety of the different classes.

PRECLINICAL SAFETY ASSESSMENT OF APTAMER THERAPEUTICS

Page Bouchard, DVM
Senior Vice President, Nonclinical Research & Development
Archemix Corporation

FROM BENCH TO BEDSIDE WITH IMMUNOSTIMULATORY Oligonucleotide Therapeutics: Issues in Drug Development

Arthur M. Krieg, MD
Senior Vice President, Research and Development
Chief Scientific Officer
Coley Pharmaceutical Group, Inc.

LOCKED NUCLEIC ACID: PROPERTIES AND THERAPEUTIC POTENTIAL

Troels Koch, PhD
Vice President, Drug Discovery & Manufacture, Santaris

12:00-1:30 PM  LUNCHEON

SESSION 3 BREAKOUTS

SESSION 3A, NONCLINICAL TRACK

GENERAL ISSUES IN SAFETY ASSESSMENT, PART 2

SESSION CHAIRPERSON

Arthur A. Levin, PhD
Senior Vice President of Development, Isis Pharmaceuticals, Inc.

This session will provide background information on the safety assessment of oligonucleotide-based therapeutics. Each speaker will address briefly what the issues are with the oligonucleotide class that they are working on and they will point out similarities and differences between the classes. The speakers will discuss briefly both how compounds are being tested as well as the results. The goal of this session is to provide the background understanding needed in order to address specific issues in the following sessions. The talks will be designed to provide all participants at the conference (clinical and manufacturing) an overview of the issues surrounding the assessment of safety of the different classes.

THE TOXICITY OF OLIGONUCLEOTIDE THERAPEUTICS: A MECHANISTIC APPROACH

Scott Henry, PhD, DABT
Vice President, Toxicology, Isis Pharmaceuticals, Inc.

SESSION 3B, CMC TRACK

ANALYTICAL CHARACTERIZATION FOR ODN THERAPEUTICS

SESSION CHAIRPERSON

Professor, Dr. Apr. Dieter Deforce
Laboratory of Pharmaceutical Biotechnology
Faculty of Pharmaceutical Sciences, University Gent, Belgium

This session will focus on the analytical challenges faced in the emerging field of oligonucleotide therapeutics. Experts from industry and academia will provide their view on analytical technology used and regulatory aspects concerning the analytical aspects for this class of therapeutics. Following the presentations a panel discussion will allow the participants to interact with the presenters.

ANALYTICAL CHALLENGES FOR ODN THERAPEUTICS AND WHAT REGULATORS WOULD EXPECT

Professor, Dr. Apr. Dieter Deforce
Laboratory of Pharmaceutical Biotechnology
Faculty of Pharmaceutical Sciences, University Gent, Belgium

ANALYTICAL CHALLENGES IN CHARACTERIZING PEGylated Oligonucleotide Drug Products

Jim Jianming Mo, PhD
Research Fellow, Analytical Research and Development
Pfizer, Inc.

CONTROLLING OLIGONUCLEOTIDE QUALITY THROUGH IDENTIFICATION OF CRITICAL IMPURITIES IN PHOSPHORAMIDITES

Claus Rentel, PhD
Associate Director, Analytical Development and Quality Control, Isis Pharmaceuticals, Inc.

SESSION 3C, CLINICAL TRACK

ADVANCES AND ISSUES IN THE DEVELOPMENT OF OLIGONUCLEOTIDES FOR THE THERAPY OF LUNG DISEASES

SESSION CHAIRPERSON

Paolo M Renzi, MD
Chief Scientific Officer and Founder, Topigen Pharmaceuticals Inc.

This session will address the current status of development of oligonucleotide programs for the therapy of lung diseases. Representative examples of oligonucleotide applications will be discussed with their advantages and their potential issues. In addition, feedback from regulatory agencies with regards to their view on issues will be given formally and during a panel discussion.

PHOSPHOROTHIOATE-BASED BACKBONE CHEMISTRY: EFFICACY AND ISSUES WITH TOPICAL DELIVERY TO THE LUNGS

Paolo Renzi, MD
Chief Scientific Officer and Founder, Topigen Pharmaceuticals Inc.
NEW CHEMISTRIES: TOXICOLOGY ISSUES IN MICE AND PLANS TO ADDRESS THEM IN HUMANS
Susan A Gregory, PhD
Vice President, Clinical Development, Isis Pharmaceuticals, Inc.

HEALTH CANADA’S EXPERIENCE WITH OLGONUCLEOTIDES, WHAT ARE THE IMPORTANT ISSUES
Gordon James Gallivan, MSc, PhD
Clinical Trials Division, Center for Evaluation of Radiopharmaceuticals and Biotherapeutics, Biologics and Genetic Therapies Directorate, Health Canada

METHODS FOR ASSESSING THE POTENTIAL TOXICITY OF OLGONUCLEOTIDES IN THE LUNGS
Sally Wenzel, MD
Professor of Medicine, Director Asthma & Allergic Diseases, University of Pittsburgh

3:00-3:30 PM REFRESHMENT BREAK

SESSION 4 BREAKOUTS

3:30-5:00 PM SESSION 4A, NONCLINICAL TRACK
SPECIFIC ISSUES IN THE SAFETY ASSESSMENT OF OLGONUCLEOTIDE-BASED THERAPEUTICS
SESSION CHAIRPERSON
S. Leigh Verbois
Pharmacologist, FDA

This session will highlight specific issues in the safety assessment of oligonucleotide based therapeutics. It is recognized that the non-clinical development of oligonucleotide-based therapeutics may include distinct considerations. Thus, to ensure the successful non-clinical development of these products, there is a need to understand and address specific toxicities that have been commonly associated with oligonucleotide-based therapeutics. This session will discuss the impact of immunogenicity, design of non-clinical studies, and current methods to enhance our understanding of toxicities associated with oligonucleotides.

ASSESSING TOXICITIES OF OLGONUCLEOTIDES: USE OF SURROGATE MOLECULES AND ANIMAL MODELS
Arthur A. Levin, PhD
Senior Vice President of Drug Development, Isis Pharmaceuticals, Inc.

ACUTE TOXICITY CONCERNS FOR OLGONUCLEOTIDES
Robert Tressler, PhD
Executive Director, Preclinical Development, Geron Corporation

IMMUNOTOXICITY AND IMMUNOGENICITY ISSUES OF NUCLEOTIDE-BASED THERAPEUTICS
Cindy L. Berman, PhD
Senior Director, Nonclinical Safety, Coley Pharmaceutical Group, Inc.

WHAT MICROARRAYS TEACH US ABOUT RNAI SPECIFICITY
Peter Linsley
Executive Director, Cancer Biology, Rosetta Inpharmatics

3:30-5:00 PM SESSION 4B, CMC TRACK
NOVEL DELIVERY SYSTEMS
SESSION CHAIRPERSON
Lilian A. Radesca, PhD
Director, Manufacturing, Alnylam Pharmaceuticals, Inc.

The potential for oligonucleotide therapeutics has grown rapidly in the last few years. Early programs focused on local drug administration leading to two product approvals (Vitravene® and Macugen®) in the US and Europe. However, to facilitate clinical ease of use, systemic as well as other more efficient direct delivery of these novel therapeutics to targeted sites are being developed, and have proved to be significantly more challenging. This session will provide a review of the creative approaches being studied to facilitate effective drug delivery to the desired cellular targets. In addition, special consideration will be given to the practical and regulatory challenges involved in the development of these novel therapeutics in complex delivery systems.

PROCESS DEVELOPMENT FOR LIPOPLEX FORMULATIONS
Maaike Vinkenburg - van Slooten, PhD
Project Leader, OctoPlus N.V.

CASE STUDY: TPI ASM8, A DUAL OLGONUCLEOTIDE DRUG PRODUCT FOR ASTHMA
Luc Paquet, PhD
Vice-President, Discovery, Topigen Pharmaceuticals

INTRATUMORAL CONVECTION ENHANCED DELIVERY OF THE TGF-BETA 2 ANTISENSE OLGONUCLEOTIDE AP 12009 IN RECURRENT HIGH-GRADE GLIOMA PATIENTS: THE WAY TO CONCLUSIVE PHASE 2 RESULTS
Hubert Heinrichs, MD
Chief Medical Officer, Antisense Pharma GmbH

CONSIDERATIONS FOR THE DEVELOPMENT OF LIPID ENCAPSULATED siRNA
Ian MacLachlan, PhD
Chief Scientific Officer, Protiva Biotherapeutics

3:30-5:00 PM SESSION 4C, CLINICAL TRACK
OLIGONUCLEOTIDES FOR INFECTIOUS DISEASES: ISSUES AND OPPORTUNITIES
SESSION CHAIRPERSON
Daniela Verthelyi, MD, PhD
Senior Staff Fellow, Division of Thereapeutics Proteins, CBER, FDA

This session will cover scientific and regulatory issues associated with the translation of pre-clinical findings from the bench to the clinic for infectious diseases indications and will review examples of representative products in ongoing clinical programs.

OLIGONUCLEOTIDES FOR INFECTIOUS DISEASES: AN OVERVIEW
Daniela Verthelyi, MD, PhD
Senior Staff Fellow, Division of Therapeutics Proteins, CBER, FDA

FDA PERSPECTIVES ON THE DEVELOPMENT OF ANTI-INFECTIVE THERAPIES
Mark J. Goldberger, PhD
Director, Office of Antimicrobial Products, CBER, FDA
Oligonucleotide-based compounds continue to hold great promise as novel therapeutic agents designed to alter biological processes utilizing a variety of mechanisms including aptameric binding to specific proteins, sequence specific immunostimulatory adjuvants, and to inhibit the production of various disease-related gene products. An understanding of the principles underlying the ADME properties of oligonucleotides is critical to understanding the biological activity of this class of compounds, and ultimately therapeutic response optimization. This session will review our current knowledge of the pharmacokinetic attributes of oligonucleotide drugs with particular attention given to oligonucleotide metabolism. Further, this session will highlight ADME’s expanding value in the discovery and development of oligonucleotide-based therapeutics.

APTAMERS: CHEMICAL MODIFICATIONS AND ADME
Renta Hutabarat, PhD
Director of Drug Metabolism and Pharmacokinetics, Archemix Corporation

IMMUNOSTIMULATORY Oligos WITH EMPHASIS OF SPECIES AND ROUTE DIFFERENCES
Brian Livingston, PhD
Director of Preclinical Research, Dynavax

THE DIFFERENCE BETWEEN SCALING UP AND MAKING BIGGER, CHALLENGES IN THE SCALE UP OF OLIGONUCLEOTIDE MANUFACTURING PROCESSES
Paul McCormac, PhD
Director of Process Development, Avecia Biotechnology

APPLICATIONS OF GREEN CHEMISTRY IN OLIGONUCLEOTIDE SYNTHESIS
Yogesh Sanghvi, PhD
President, Rasayan Inc.

NEW ANALYTICAL METHOD FOR THE DETECTION OF SINGLE STRANDED IMPURITIES IN DUPLEX ASOS
Huseyin Aygün, PhD
Chief Scientific Officer, BioSpring Gmbh

MANUFACTURING OLIGONUCLEOTIDE API’S – IDENTIFICATION OF PROCESS-RELATED IMPURITIES
Kenneth Hill, PhD
Director of Process Development, Agilent Technologies Inc.

Oligonucleotide manufacturing technology has progressed quite a bit in the past few years, with two approved oligonucleotide molecules in the market, and many more in the pipeline. The task of manufacturing low-cost oligonucleotide medicines still remains. This session will address the challenges of synthesizing and scaling up key raw materials as well as the formation and removal of impurities during synthesis and post-synthesis purification. We will also examine the relationship of different process parameters and its predictability by scaled down systems.

This session will provide insight into the issues in developing oligonucleotide therapeutics for chronic diseases like diabetes, cardiovascular disease and muscular dystrophy. The metabolic and cardiovascular drugs show interesting activities and face unique challenges in that there are existing drugs for these indications. In contrast, the agents being used for the treatment of muscular dystrophy use a different mechanism of action (splicing inhibition) and may need to be tailored to each patient. How each of these therapeutic agents are being developed provides examples for different regulatory and developmental hurdles.
DEVELOPING ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF TYPE 2 DIABETES
Sanjay Bhanot, MD, PhD
Vice President, Drug Development, Isis Pharmaceuticals, Inc.

TREATING HYPERCHOLESTEROLEMIA BY INHIBITING THE EXPRESSION OF APOLIPOPROTEIN B EXPRESSION. RECENT CLINICAL RESULTS AND CHALLENGES AHEAD
Diane Tribble, PhD
Vice President, Clinical Development, Isis Pharmaceuticals, Inc.

USING ANTISENSE AGENTS TO ALTER SPLICING IN DUCHENNE’S MUSCULAR DYSTROPHY: CAN ANTISENSE PROVIDE INDIVIDUALIZED THERAPY?
Steve Wilton, PhD
Professor of Molecular Medicine, University of Western Australia

ISSUES IN ANTISENSE: ASO THAT ALTER mRNA SPLICING IN DUCHENNES MUSCULAR DYSTROPHY
Sjef de Kimpe, PhD, MBA
Prosensa BV

10:00-10:30 AM REFRESHMENT BREAK

SESSION 6 BREAKOUT SESSIONS

10:30 AM-12:00 PM SESSION 6A, NONCLINICAL TRACK
SPECIFIC ISSUES IN ADME
SESSION CHAIRPERSONS
J. Neil Duncan, PhD
Research Fellow, Preclinical PDM, Pfizer, Inc
Joy Cavagnaro PhD, DABT, RAC
Access BIO

This session will cover issues associated with the generation of PK data for ODN drugs, the relevance of such data in deriving PK/PD relationships and the potential impact and utility of different approaches to drug delivery. Bioanalytical strategies are influenced by varied analyte sensitivity and selectivity requirements for different types of ODN necessitating selection of appropriate analytical technologies. The importance of appropriate systemic PK assessment in generation of useful PK/PD relationships, the rationale for initial dose and schedule selection and the application of new delivery technologies to facilitate different routes of administration will also be discussed.

ISSUES IN THE BIOANALYSIS OF ODN MOLECULES. METHODOLOGIES EMPLOYED: SENSITIVITY VERSUS SELECTIVITY CONSIDERATIONS
Rand Jenkins
Director, Research and Development, PPD

IMPLICATIONS AND CHALLENGES IN PK/PD OF ODNs
Huiying Xu, PhD
Clinical Pharmacology, Pfizer, Inc

ODN (ANTISENSE AND ANTIGENE) AND siRNA DELIVERY AND TARGETING
Ram I. Mahato, PhD
Associate Professor, University of Tennessee Health Science Center

10:30 AM-12:00 PM SESSION 6B, CMC TRACK
CMC REGULATORY CONSIDERATIONS AND PANEL DISCUSSION – PART 1
SESSION CHAIRPERSONS
Ramesh Raghavachari, PhD
Chemist, ONDQ/DPE/Branch 7, FDA
James V. McArdle, PhD
Vice President, Chemistry, Manufacturing, and Controls, Archemix Corporation

In this session we will discuss, from the perspective of the regulatory agencies and industry, a number of CMC regulatory concerns, including:

- Establishing meaningful specifications
- Managing stringent yet practical acceptance criteria for impurities
- Proving sequences
- Validating methods for the commercial quality control lab
- Understanding mechanisms of degradation and establishing shelf lives
- Managing changes to synthetic processes and manufacturing routes
- Mitigating risk all the way from an unsettled supply chain through end of shelf life

FDA PERSPECTIVE
Rao Kambhampati
Senior Regulatory Review Scientist, FDA

CMC REQUIREMENTS FOR OLIGONUCLEOTIDES IN EUROPE
René Thürmer, PhD
BfArM – Federal Institute for Drugs and Medical Devices, Germany

REGULATORY CMC CONSIDERATIONS FOR OLIGONUCLEOTIDES
Todd Meyer
Global Biologics, Pfizer, Inc

10:30 AM-12:00 PM SESSION 6C, CLINICAL TRACK
CLINICAL AND REGULATORY CHALLENGES OF ANTISENSE AND ANTISENSE-LIKE TECHNOLOGIES IN CLINICAL ONCOLOGY
SESSION CHAIRPERSON
Adrian M. Senderowicz
Medical Offices of Oncology Drug Products, Office of New Drugs, CDER, FDA

The attendees will learn requirements for drug approval in medical oncology. Furthermore, attendees will learn about recent antisense submissions to the FDA and Health Canada. Discussions about these submissions may lead to the incorporation of novel agents from this class in the therapeutic armamentarium. Finally, the attendees will learn about early-stage antisense compounds and recent advances in the preclinical field as well as the future of anti-sense and anti-sense like technologies.

OVERVIEW OF CLINICAL AND REGULATORY CHALLENGES OF ANTISENSE AND ANTISENSE-LIKE TECHNOLOGIES IN CLINICAL ONCOLOGY, FDA PERSPECTIVE
Adrian M. Senderowicz
Medical Offices of Oncology Drug Products, Office of New Drugs, CDER, FDA
OLIGONUCLEOTIDES IN ONCOLOGY: HEALTH CANADA
PERSPECTIVE FOCUS ON CLINICAL TRIALS
Christine Nestruck, MSc, PhD
Assessment Officer
Office of Clinical Trials, Clinical Group 1
Therapeutic Products Directorate
Health Products and Food Branch
Health Canada

OVERVIEW OF NCI PORTFOLIO AND NCI PERSPECTIVE
Igor Espinoza-Delgado, MD
Senior Clinical Investigator
Cancer Therapy Evaluation Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute

ANTISENSE AND ANTISENSE-LIKE TECHNOLOGIES IN ONCOLOGY:
THE FUTURE
Kerry L. Blanchard, PhD, MD
Executive Director, Discovery Biology Research
Eli Lilly and Company

12:00-1:30 PM LUNCHEON

1:30-3:00 PM SESSION 7 BREAKOUTS

CMC REGULATORY CONSIDERATIONS AND PANEL DISCUSSION – PART 2
SESSION CHAIRPERSONS
Ramesh Raghavachari, PhD
Chemist, ONDQ/DPE/Branch 7, FDA
James V. McArdle, PhD
Vice President, Chemistry, Manufacturing, and Controls
Archemix Corporation

In this session we will discuss, from the perspective of the regulatory agencies and industry, a number of CMC regulatory concerns, including:

- Establishing meaningful specifications
- Managing stringent yet practical acceptance criteria for impurities
- Proving sequences
- Validating methods for the commercial quality control lab
- Understanding mechanisms of degradation and establishing shelf lives
- Managing changes to synthetic processes and manufacturing routes
- Mitigating risk all the way from an unsettled supply chain through end of shelf life

Panel Discussion
Todd Meyer
René Thürmer
Rao Kambhampati
Ulrich Granzer
Amit Banerjee
Lilian Radescu
Dieter Deforce
Susan Srivatsa

1:30-3:00 PM SESSION 7C, CLINICAL TRACK

OLIGONUCLEOTIDES – EMERGING THERAPIES IN TREATMENT OF RETINAL DISEASES
SESSION CHAIRPERSON
Peter Hnik, MD, MHSc
Chief Medical Officer, iCo Therapeutics, Inc.

This session will provide pre-clinical and clinical review of experience with oligonucleotides in the eye. Potential advantages in treatment of retinal diseases will be discussed as well as feedback from regulatory agencies on potential issues with these compounds during the regulatory process.

TOLERABILITY AND PHARMACOKINETICS OF ANTISENSE OLIGONUCLEOTIDES ADMINISTERED BY INTRAVITREAL INJECTION IN ANIMAL MODELS
Scott Henry, PhD, DABT
Vice President, Toxicology, Isis Pharmaceuticals, Inc.

TARGETS FOR OLIGONUCLEOTIDE THERAPIES FOR RETINAL DISEASES
Karl G. Csaky, MD, PhD
Associate Professor of Ophthalmology
Director, Ophthalmic Unit DCRI, Duke University Medical Center

LOCAL PROTEIN EXPRESSION SYSTEMS IN THE EYE
Lisa L. Wei, PhD
Director, Preclinical Sciences, GenVec, Inc.

iCo-007, A VEGF "++" AGENT FOR POTENTIAL TREATMENT OF DIABETIC MACULAR EDEMA, DIABETIC RETINOPATHY AND AGE-RELATED MACULAR DEGENERATION
Peter Hnik, MD, MHSc
Chief Medical Officer, iCo Therapeutics Inc.

1:30-3:00 PM SESSION 7D, CLINICAL TRACK

USE OF ODN TLR9 AGONISTS AS VACCINE ADJUVANTS: CLINICAL EXPERIENCE
SESSION CHAIRPERSON
Nathalie Garçon, PharmD, PhD
Vice President, Research and North America Research and Development, GlaxoSmithKline Biologicals

This session will cover pre-clinical and clinical experience of TLR9 agonist oligodeoxynucleotides that have been tested clinically as adjuvants to infectious disease and cancer vaccines. Potential advantages over currently available adjuvants will be discussed as well as feedback from regulatory agencies on potential issues with these compounds during the regulatory process.

EXPERIENCE WITH A CPG OLIGONUCLEOTIDE AS AN ADJUVANT TO A PROPHYLACTIC HEPATITIS B VACCINE IN HEALTHY VOLUNTEERS AND HIV-INFECTED PATIENTS
Heather L. Davis, PhD
Senior Vice President Pharmacology R&D
Coley Pharmaceutical Group, Inc.

EXPERIENCE WITH A CPG ADJUVANT IN MALARIA VACCINES
Ruth D. Ellis, MD, MPH
Staff Clinician, Malaria Vaccine Development Branch
NIAID/NIH
CHARACTERIZATION OF NEXT GENERATION ANTHRAX AND INFLUENZA VACCINES UTILIZING IMMUNOSTIMULATORY OLGONUCLEOTIDES AS ADJUVANTS
Brian Livingston, PhD
Director, Preclinical Research, Dynavax Technologies Corp.

CANCER VACCINE TRIALS WITH CpG ADJUVANT: THE LUDWIG INSTITUTE/CANCER RESEARCH INSTITUTE EXPERIENCE
Eric W. Hoffman, PharmD
Director, Office of Clinical Trials Management, Ludwig Institute for Cancer Research

REGULATORY CONSIDERATIONS FOR USE OF OLGONUCLEOTIDES IN VACCINE FORMULATIONS
Maria Baca-Estrada, PhD
Chief, Bacterial Vaccines Division, Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada

3:00-3:30 PM  REFRESHMENT BREAK

3:30-3:45 PM  KEYNOTE ADDRESS
FDA’S CRITICAL PATH AND THE PROMISE OF NEW SCIENCE
Douglas C. Throckmorton, MD
Deputy Director, CDER
FDA

3:45-5:30 PM  SESSION 8
NONCLINICAL AND CLINICAL NEXT STEPS
SESSION CHAIRPERSON
David H. Schubert
Vice President, Regulatory Affairs and Global Quality Assurance Coley Pharmaceutical Group, Inc.

Led by discussants, this plenary session will review with health authorities and industry expert panel the challenges and issues associated with the nonclinical and clinical development of ODN-based therapeutics brought forth in this conference. Panel Members will discuss and propose next steps in the further development of therapies using these new drug classes.

NONCLINICAL DISCUSSANT
Arthur A. Levin, PhD
Senior Vice President of Drug Development, Isis Pharmaceuticals, Inc.

CLINICAL DISCUSSANT
Paolo Renzi, MD
Professor University of Montreal
Chief Scientific Officer and Founder Topigen Pharmaceuticals Inc.

PANEL MEMBER DISCUSSION
FDA Representatives
Sally Seymour
Abigail Jacobs
David Jacobson-Kram

HPFB Representatives
Agnes Klein
Jim Gallivan
Christine Nestruck

Academic Representatives
Steve Wilton
Sally Wenzel

Industry Representatives
Art Levin
Art Krieg
Douglas Kornbrust

5:30-5:45 PM  CLOSING REMARKS
5:45 PM  CONFERENCE ADJOURNED

Statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association. Speakers and agenda are subject to change without notice.

Recording of information, in any type of media, is prohibited at all DIA events without prior written consent from DIA.

TRAVEL AND HOTEL. The most convenient airport is Reagan National Airport and attendees should make airline reservations as early as possible to ensure availability. The DoubleTree Hotel and Executive Meeting Center Bethesda is holding a block of rooms at the reduced rate below until March 26, 2007, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.

Single $239  Double $239

Please contact The DoubleTree Hotel and Executive Meeting Center Bethesda by telephone at +1-800-222-TREE or +1-301-652-2000 and mention the DIA event. The hotel is located at 8120 Wisconsin Avenue, Bethesda, MD 20814, USA.

UNITED AIRLINES & US AIRWAYS
Save through Area Pricing and Discount Fees
To obtain schedule information and the best fares, call United Airlines’ Specialized Meeting Reservations Center at 1-800-521-4041. Make sure you refer to Meeting ID Number 571AK. Dedicated reservationists are on duty 7 days a week from 8:00 AM to 10:00 PM EST.

This special offer applies to travel on domestic segments of all United Airlines, United Express, PED, and United code share flights (UA*, operated by US Airways, US Airways Express and Air Canada).

CONTACT INFORMATION
Contact Joanne Wallace at the DIA office by telephone +1-215-442-6180, fax +1-215-442-6199 or email Joanne.Wallace@diahome.org.

Participants with Disabilities: DIA event facilities and overnight accommodations are accessible to persons with disabilities. Services will be made available to sensory-impaired persons attending the event if requested at least 15 days prior to event. Contact the DIA office to indicate your needs.

DRUG INFORMATION ASSOCIATION  http://www.diahome.org

Horsham, PA, USA
Tel: +1-215-442-6100  Fax: +1-215-442-6199
email: dia@diahome.org

Basel, Switzerland
Tel: +41-61-225-51-51  Fax: +41-61-225-51-52
email: diaeurope@diahune.org

Tokyo, Japan
Tel: +81-3-5511-1131  Fax: +81-3-5511-0100
email: diajapan@diahjapan.org
**Industry and Health Authority Conference on: Oligonucleotides-based Therapeutics**

Event ID #07010  
DoubleTree Hotel and Executive Meeting Center Bethesda, Bethesda, MD, USA  
APRIL 19-20, 2007

---

**REGISTRATION FORM**  
Do not remove mailing label. Please return this entire page.  
07010

**PLEASE CONSIDER THIS FORM AN INVOICE**

Industry and Health Authority Conference on: 
Oligonucleotides-based Therapeutics  
Meeting I.D. # 07010 – April 19-20, 2007  
DoubleTree Hotel and Executive Meeting Center Bethesda, Bethesda, MD, USA

**Registration Fees**  
Registration fee includes refreshment breaks, luncheons, and reception (if applicable), and will be accepted by mail, fax, or online.

<table>
<thead>
<tr>
<th>Fee Type</th>
<th>Fee</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry Fee</td>
<td>US $1165</td>
<td></td>
</tr>
<tr>
<td>Join DIA now to save on future events and to receive all the benefits of membership.</td>
<td>US $130</td>
<td>MEMBERSHIP</td>
</tr>
</tbody>
</table>

**Discount Fees**

<table>
<thead>
<tr>
<th>Fee Type</th>
<th>Fee</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government (Full-time)</td>
<td>US $200</td>
<td></td>
</tr>
<tr>
<td>Charitable Nonprofit/Academia (Full-time)</td>
<td>US $475</td>
<td></td>
</tr>
</tbody>
</table>

**CANCELLATION POLICY:** On or before APRIL 13, 2007  
Administrative fee that will be withheld from refund amount:  
Member or Nonmember = $200  
Government or Academic or Nonprofit (Member or Nonmember) = $100  
Tutorial = $50  
Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

**DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.**

**I cannot attend but please keep me informed of DIA’s future events.**  
(required completion of name, postal address and email address on this form)

**PAYMENT OPTIONS**  
Register online at www.diahome.org or check payment method  
DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

**CONTACT INFORMATION**  
Event information: Contact Joanne Wallace at the DIA office by telephone +1-215-442-6180, fax +1-215-442-6199 or email Joanne.Wallace@diahome.org.

---

**DRUG INFORMATION ASSOCIATION**  
800 Enterprise Road, Suite 200  
Horsham, PA 19044-3595 USA

---

**Drug Information Association**  
www.diahome.org